# Synthetic cytokine receptors

Source: https://onco.cc/terms/synthetic-cytokine-receptors/  
OnCo record `synthetic-cytokine-receptors` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

An engineered cytokine receptor connects a specified input to signalling inside a cell. The added signal and the behaviour of the complete cell product need separate measurements.

## Summary

A synthetic cytokine receptor is an engineered cell-surface protein that connects a specified input to intracellular signalling. It differs from engineering a soluble cytokine or simply administering a cytokine. Some designs require an externally supplied ligand; others generate ligand-independent signalling. The receptor domains, input, expression and cell type define the tested construct. A growth-supporting signal does not itself establish antigen recognition, entry into a tumour, completed killing or durable patient benefit.

## Fields

- Kind: Term
- Last checked: 2026-11-12
- Also known as: engineered cytokine receptors; chimeric cytokine receptors; SyCyR

## Notes

- Engelowski and colleagues joined fluorescent-protein-binding nanobodies to selected cytokine-receptor membrane and intracellular domains. Artificial GFP/mCherry-based ligands induced signalling in experimental systems. That 2018 study is a particular ligand-dependent design, not a test of every synthetic receptor or of a company platform with a different architecture.
- In a 2010 human T-cell study, a chimeric receptor joined the IL-4 receptor binding region to an IL-2/IL-15 receptor signalling component. IL-4 supported expansion of the engineered cells, while a separate CAR specified the tumour target. The reported culture experiments distinguished expansion, cytokine dependence and target-cell killing; they were not patient efficacy results.
- A 2026 macrophage preprint studied ligand-independent receptors with varied signalling motifs in primary human macrophages and preclinical models. Marker expression, phagocytosis and mouse tumour observations were different readouts. The report remains a preprint and does not establish human treatment benefit.
- Enoda uses MIMIC as the name of its synthetic cytokine-receptor assets. The platform name does not define all engineered cytokine receptors or establish clinical performance. Its website describes platform aims and sponsor claims; it is not a comparative clinical safety or efficacy report.
- For a drug-gated construct, withdrawing the input can reduce a selected signal without eliminating cells already engineered. Receptor signalling, viable-cell counts, tissue location, target-cell killing and later disease control need distinct measurements. A growth or activity switch is different from a cell-elimination mechanism.
- A mechanistic schematic shows an intended arrangement. It is not a measurement of receptor expression, signalling, cell killing or patient outcome; each of those requires its own evidence.
- In a fictional comparison with equal starting viable-cell input and the same CAR, a supplied trigger produces 250 viable cells at 48 hours versus 100 without it. That is 2.5 times the viable-cell count, not 2.5 times the treatment benefit. Tumour killing changes from 20 to 25 per cent, while a separate healthy-cell assay changes from two to 18 per cent injury. Count division, survival and loss separately, retain each assay’s target-cell denominator and uncertainty, and do not combine these results into a whole-body safety window.
- Read each supportive feature as a testable hypothesis. A drug-triggered signal needs a baseline and a withdrawal test; an antigen-triggered signal needs testing after cells leave the priming site. Constitutive signalling raises different growth and cell-state questions, while a secreted payload can affect neighbouring cells or circulate. Orthogonal means sufficiently separate from natural partners under tested conditions, not selectivity established by its name. The supportive receptor does not specify the CAR target, and changing an internal signal is different from secreting a cytokine. An added support signal does not by itself demonstrate adequate oxygen, tissue access, recognition of an absent antigen or patient benefit.

## Sources

- Engelowski 2018: artificial ligands and synthetic receptors in experimental systems: https://pubmed.ncbi.nlm.nih.gov/29789554/
- Wilkie 2010: IL-4-driven expansion and separate CAR targeting in human-cell experiments: https://pubmed.ncbi.nlm.nih.gov/20562098/
- Lunger 2026 macrophage receptor preprint; not a clinical report: https://pubmed.ncbi.nlm.nih.gov/42182394/
- Enoda: MIMIC platform description; sponsor naming and claims: https://www.enoda.bio/
- Wu et al.: small-molecule ON-switch CAR experiments (2015): https://pubmed.ncbi.nlm.nih.gov/26405231/
- FDA: Considerations for the Development of CAR T Cell Products (January 2024): https://www.fda.gov/media/156896/download
- Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma. (2015): https://pubmed.ncbi.nlm.nih.gov/25695689/

## Connected records

- technologies: [Armoured, logic-gated & next-gen CARs](https://onco.cc/technologies/armored-car/), [Cell-therapy safety switches](https://onco.cc/technologies/safety-switch-car-t/), [In vivo CAR-T](https://onco.cc/technologies/in-vivo-car-t/)
- terms: [Cellular kinetics and persistence](https://onco.cc/terms/cellular-kinetics-and-persistence/), [Cytokine](https://onco.cc/terms/cytokine/)

---
JSON: https://onco.cc/api/v1/entities/synthetic-cytokine-receptors.json